Bristol-Myers Squibb (BMY) Tops Q3 EPS by 17c, Beats on Revenue, Offers FY22 Revenue Guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $64.65 +1.49%
Financial Fact:
Research and development: 1.14B
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Research and development: 1.14B
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $1.99, $0.17 better than the analyst estimate of $1.82. Revenue for the quarter came in at $11.22 billion versus the consensus estimate of $11.15 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2022 revenue of $46 billion, versus the consensus of $46 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
- Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
